For these reasons, second‐generation recombinant enzymes with improved targeting properties or pharmacodynamics are currently under development, for example, avalglucosidase‐apha, a glycoengineered GAA, for the treatment of Pompe disease (Pena et al, 2019; Xu et al, 2019) and pegunigalsidase alfa, a PEGylated covalently cross‐linked alpha‐galactosidase A, for the treatment of Fabry disease (Schiffmann et al, 2019). This evidence concerns the gene GLA and Fabry disease.